Author:

• Rondineli Mendes da Silva - Silva, R.M. - Escola Nacional de Saúde Pública Sérgio Arouca (ENSP) - <rondineli.mendes@gmail.com>
ORCID: https://orcid.org/0000-0002-6243-5179

Co-author(s):

• Isabel Cristina Martins Emmerick - Emmerick, Isabel Cristina Martins - Harvard Medical School - <emmerick.isabel@gmail.com>
ORCID: https://orcid.org/0000-0002-0383-2465
• Dennis Ross-Degnan - Ross-Degnan, Dennis - Harvard Medical School & Harvard Pilgrim Health Care Institute - <Dennis_Ross-Degnan@hms.harvard.edu>
• Vera Lucia Luiza - Lucia Luiza, Vera - Rio de Janeiro, - Fundação Oswaldo Cruz (Fiocruz) / Escola Nacional de Saúde Pública Sergio Arouca (Ensp) - <vera@ensp.fiocruz.br> +
ORCID: https://orcid.org/0000-0001-6245-7522
• Andréa Dâmaso Bertoldi - Bertoldi, A.D - Universidade Federal de Pelotas (UFPel) - <andreadamaso.epi@gmail.com>
ORCID: https://orcid.org/0000-0002-4680-3197
• MONICA RODRIGUES CAMPOS - Campos, M. R. - ENSP - <monicarodriguescampos@gmail.com>
ORCID: https://orcid.org/0000-0002-7443-5977
• Gabriela Costa Chaves - Costa Chaves, Gabriela - Escola Nacional de Saude Publica, Departamento de Politica de Medicamentos e Assistência Farmacêutica - <gabicostachaves@ensp.fiocruz.br>
• Luisa Arueira - Arueira, Luisa - Universidade Federal do Rio de Janeiro, UFRJ - <luisa.arueira@gmail.com>

Thematic Area:

Não Categorizado

Abstract:

This paper aims to analyse changes in the retail pharmaceutical market following policy changes in the Farmácia Popular Program (FP), a medicines subsidy program in Brazil. The retrospective longitudinal analyses focus on therapeutic class of agents acting on the renin-angiotensin system. Data obtainedQuintilesIMS (formerly IMS Health) included private retail pharmacy sales volume (pharmaceutical units) and sales values2002 to 2013. Analyses evaluated changes in market share following key FP policy changes. The therapeutic class was ed due to its relevance to hypertension treatment. Market share was analysed by therapeutic sub-classes and by individual company. Losartan as a single product accounted for the highest market share among angiotensin II antagonists. National companies had higher sales volume during the study period, while multinational companies had higher sales value. Changes in pharmaceutical market share during the study period coincided with the inclusion of specific products in the list of medicines covered by FP and with increases in or exemptionpatient copayment.

Keywords:

Pharmaceutical TradeAntihypertensive AgentsInterrupted Time Series AnalysisPharmaceutical ServicesGovernment Programs

Content:

Access Issue in Scielo

Other languages: